Cannabis Science Inc (OTCMKTS:CBIS) has plans to start a long anticipated medication trial for pulmonary patients seeing changing failing lung functions coming from Bronchitis to Cancers and all in between respiratory diseases.

Raymond C. Dabney, the CEO, said that they anticipate it will commence subsequent to the completion of the First Lab and Extraction site and they believe it to happen soon. The firm’s goals along with drugs are the delivery systems mandatory and considered to be helpful to the people. While treatments in inhaled medications or pill form serve well for long term regimens and maintenance purposes, often a medication’s healing benefit is not noted through the delivery mechanism. While this does not remove the need for maintenance type and quick relief medicines, a targeted method for disease is not only option but a requirement.

Another firm in the same sector, Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) has initiated the study in Israel for patients suffering with cancer utilizing company’ SR Capsules. It is one of the only clinical trial explicitly investigating the impact of cannabis using a medically standardized edible supply system. The firm states itself as an approved research and development unit based in Israel committed to the advancement of palliative and personalized anti-cancer therapies harnessing the versatile medicinal values of cannabinoids to cure tailored treatments for cancer patients.

After the recent historical vote, the markets expect cannabis industry to become the fastest-growing industry in the nation. ArcView Market Research revealed another report, which entails predictions of the legal cannabis market predicting it will post annual revenue of $21.8 billion by 2020.

The research group even made comparison of the approved marijuana industry which could excel national Football League, which noted almost $12 billion of sales last year but is indicating to hit $25 billion by 2027. In addition, 60% of Americans want to approve cannabis with a jump of 31% compared to 2000.